HCM
PBYI icon

Highbridge Capital Management’s Puma Biotechnology PBYI Stock Holding History

Highbridge Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-73,864
Closed -$2.27M – 1637
2016
Q4 		$2.27M Buy
73,864
+66,985
+974% +$2.9M 0.04% 365
2016
Q3 		$462K Buy
+6,879
New +$348K 0.01% 820
2016
Q1 		– Sell
-73,899
Closed -$5.79M – 1738
2015
Q4 		$5.79M Buy
+73,899
New +$5.8M 0.09% 252
2015
Q1 		– Sell
-2,384
Closed -$451K – 1541
2014
Q4 		$451K Buy
+2,384
New +$529K 0.01% 853

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Highbridge Capital Management's PBYI Position: Q1 2017 in Review

Highbridge Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2017, closing a stake of 73,864 shares — an estimated $2.27M sold.

Highbridge Capital Management first reported a position in PBYI in Q4 2014 and held it in 4 quarters. The position peaked at $5.79M in Q4 2015. 136 funds tracked by Wall St. Rank hold PBYI as of Q1 2017.

  • Highbridge Capital Management reported no remaining Puma Biotechnology position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 73,864 Puma Biotechnology shares in Q1 2017, an estimated $2.27M.
  • Highbridge Capital Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 4 quarters.
  • Highbridge Capital Management's Puma Biotechnology position peaked at $5.79M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.